Aclaris Therapeutics Inc (ACRS) Event Aug. 03, 2022, 00:00 UTC (28% Negative) Aclaris Therapeutics, Inc. (ACRS) Reports Net Loss for 2022-06-30 Full text
Register to leave comments News bot Oct. 29, 2025, 10:38 a.m. 🏢 Aclaris Therapeutics Inc (ACRS) - Form 10-Q Quarterly Report Quarterly financial filing submitted to the SEC 📋 Filing Information 📄 Form Type: 10-Q 📅 Filing Date: 2022-08-03 📊 Period of Report: 2022-06-30 ⏰ Accepted: N/A 📊 Key Financial Metrics (Period-over-Period Comparison) Metric Current Period Previous Period Change ($) Change (%) Trend Net Income/Loss $-46.91M $-39.32M $-7.59M -19.31% 📈 Total Assets $251.21M $277.98M $-26.77M -9.63% 📉 Total Liabilities $53.87M $42.22M $11.65M +27.58% 📉 Stockholders' Equity $233.81M $-551.46M $785.27M +142.40% 📈 Operating Income/Loss $-46.53M $-9.19M $-37.34M -406.31% 📈 R&D Expense $15.73M $-211.00K $15.95M +7557.35% 📉 Earningspersharebasic $-0.90 $-0.62 $-0.28 -45.16% 📉 Earningspersharediluted $-0.90 $-0.62 $-0.28 -45.16% 📉 Costofrevenue $2.46M $-3.33M $5.79M +174.07% 📈 📈 Financial Trend Analysis 🔻 Reported net loss for the period • ⚖️ Liability growth outpaced asset growth 📎 View Full 10-Q Filing on SEC.gov Access the complete official filing document
🏢 Aclaris Therapeutics Inc (ACRS) - Form 10-Q Quarterly Report
📋 Filing Information
Key Financial Metrics (Period-over-Period Comparison)
Financial Trend Analysis
🔻 Reported net loss for the period • ⚖️ Liability growth outpaced asset growth
📎 View Full 10-Q Filing on SEC.gov
Access the complete official filing document